aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company (“aVenture”) is an independent research platform providing information and analysis about startups.
Certain metrics provided by aVenture may seek to assess the risks and opportunities associated with a company, fund, or its representatives (collectively “research”). aVenture seeks to provide this information with objectivity and fairness, and with diligence about its accuracy. Nonetheless, aVenture cannot provide assurance as to the accuracy of the information provided by our research. We strongly advise those using the research platform to seek multiple, independent sources for your research when making financial decisions.
Any links provided to other websites are offered as a matter of convenience and are not intended to imply that aVenture or its authors endorse, sponsor, promote, and/or are affiliated with the owners of or participants in those sites.
The aVenture platform also provides investment listings offered by independent investment advisers in the United States. aVenture is neither a registered investment adviser nor an exempt reporting adviser under the Investment Advisers Act of 1940, and no statements made by aVenture are intended to imply any financial instruments are under the counsel or advice of aVenture or its representatives.
Funds offered on the platform are generally managed by a private investment adviser that, unless stated otherwise, claims exemption from SEC or state registration. Investment funds presented on the platform are only available to investors who meet the requirements of the offering, and solicitations are not made outside those listed jurisdictions.
Additionally, each investment offered on the platform has qualifications for eligibility, including some offered only to Qualified Clients and/or Accredited Investors. Certain funds may be available to non-Qualified or Accredited investors, but only those who become personally known and identifiable to aVenture Investment Company staff, who have had an opportunity to assess the financial capacity and suitability for such an investment, and discuss its risks. Funds, when offered, are only offered following a review of a Private Placement Memorandum (PPM), subscription agreement, and other disclosures.
Investments in startups, venture capital, angel investments, private equity, real estate, stocks, and similar asset classes all involve risks, including: the risk of a decline in the value of your investments, including potentially large declines (suddenly and/or for long periods of time), the potential for illiquidity where part or all of a withdrawal request may not be honored on the date requested (even when a feature of the fund). These risks are heightened during periods of market duress.
Diversification has the possibility of reducing the magnitude of declines (either caused by market/economic factors, or by factors related to the individual company), but does not guarantee these risks have been fully or partially alleviated. Most importantly, past results are not an assurance of future outcomes. While most of these risks are shared and similarly held by other investment asset classes, we recommend investors only consider venture capital investments as part of a broader, diversified portfolio of stocks, bonds, and immediately accessible cash reserves.
From Startups | TechCrunch
By Romain Dillet
March 26, 2024
Here’s the harsh truth behind personal care products: You’re mostly buying water and plastic. The main ingredient in a bottle of shampoo or shower gel is water, which is then mixed with a bunch of active ingredients. And because it’s a “pre-mixed” product, companies spend a lot of money on plastic bottles to transport those products to your bathroom.
French startup 900.care wants to try something new. Instead of buying a new bottle of shower gel every time you need some shower gel, the startup focuses on the active ingredients.
On your first order, you receive an empty, reusable plastic bottle with a pump. You put a tiny stick of compacted powder in the bottle, add some water and wait a few hours. It’s then ready to use. The next time you need more shower gel or shampoo, you only need a new stick (and some tap water).
“You keep all the benefits of using shower gel, for example. Our shower gel lathers, it has the same texture, it smells good, etc. But you didn’t buy any plastic and you didn’t carry any water,” co-founder and CEO Aymeric Grange told me.
And 900.care raised a €21 million funding round a couple of months ago ($23 million at today’s exchange rate), as its products have been working pretty well in its home country. Lombard Odier Investment Managers is leading the funding round with existing investors White Star Capital, Swen Blue Ocean and Founders Future also participating.
The startup followed the direct-to-consumer playbook, as customers can only buy products on its website. As you always need new personal care products, the company also decided to sell its products as subscriptions exclusively.
In 2023 alone, 900.care generated €10 million in revenue ($10.8 million). The startup has 90,000 clients with 235,000 active subscriptions — each client can have multiple subscriptions.
In addition to shampoo and shower gel, 900.care also sells foaming hand soap, dish soap, laundry and dishwasher tablets, as well as a few other products. The company estimates that it prevented the equivalent of 3.5 million plastic bottles of waste.
The company’s products also represent a good business opportunity. Every few weeks, customers receive an envelope with new sticks for their hygiene and home products. Because those compacted powder sticks are quite small, they fit in a normal envelope and can be sent as normal mail, which saves 900.care money on shipping fees.
Similarly, factories and production lines are quite small, as they don’t need huge basins to mix water with active ingredients. They only need to mix up different powders and compact the mix to turn it into tiny sticks.
“For the compacting and industrialization stage, the big challenge was that there was no one who knew how to do that. Initially, we started working with people who were involved in cosmetics,” Grange said. “But we soon realized that this wasn’t going to work. They couldn’t keep up with the pace, and the factories weren’t designed for it. So during the second quarter of 2023, we opened a factory in Saint-Etienne, dedicated to compacted powder.”
This new factory will work exclusively for 900.care but is still operated by a partner. But the fact that everything has been specifically designed for 900.care has greatly improved the company’s margins.
The startup thinks it can reach €100 million in revenue within three years, as it is about to expand to other European countries beyond France, Belgium and Switzerland. But the company still expects to turn a profit this year.
View original article on techcrunch.com
Share:
Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs
Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery. On Tuesday, ARCH Venture Partners and Foresite Labs, an affiliate of Foresite Capital, announced that they incubated Xaira Therapeutics and funded the AI biotech with $1 billion. Other investors […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 25, 2024
Eric Schmidt-backed Augment, a GitHub Copilot rival, launches out of stealth with $252M
AI is supercharging coding — and developers are embracing it. In a recent StackOverflow poll, 44% of software engineers said that they use AI tools as part of their development processes now and 26% plan to soon. Gartner estimates that over half of organizations are currently piloting or have already deployed AI-driven coding assistants, and […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 24, 2024
Radical thinks the time has come for solar-powered, high-altitude autonomous aircraft
Though many eyes are on space as orbit develops into a thriving business ecosystem, Radical is keeping things a little closer to the ground — but not too close. Its high-altitude, solar-powered aircraft aim to succeed where Facebook’s infamous Aquila failed by refining the tech and embracing more markets. It’s hard to believe that Facebook’s […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 24, 2024
Don't miss our latest news and updates. Subscribe to the newsletter
More from Tech Crunch: